Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

467 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom.
Spelman T, Herring WL, Zhang Y, Tempest M, Pearson I, Freudensprung U, Acosta C, Dort T, Hyde R, Havrdova E, Horakova D, Trojano M, De Luca G, Lugaresi A, Izquierdo G, Grammond P, Duquette P, Alroughani R, Pucci E, Granella F, Lechner-Scott J, Sola P, Ferraro D, Grand'Maison F, Terzi M, Rozsa C, Boz C, Hupperts R, Van Pesch V, Oreja-Guevara C, van der Walt A, Jokubaitis VG, Kalincik T, Butzkueven H; MSBase Investigators. Spelman T, et al. Among authors: trojano m. Pharmacoeconomics. 2022 Mar;40(3):323-339. doi: 10.1007/s40273-021-01106-6. Epub 2021 Dec 18. Pharmacoeconomics. 2022. PMID: 34921350 Free PMC article.
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA; TRANSFORMS Study Group. Khatri B, et al. Lancet Neurol. 2011 Jun;10(6):520-9. doi: 10.1016/S1474-4422(11)70099-0. Epub 2011 May 13. Lancet Neurol. 2011. PMID: 21571593 Clinical Trial.
Anxiety and depression in multiple sclerosis patients around diagnosis.
Giordano A, Granella F, Lugaresi A, Martinelli V, Trojano M, Confalonieri P, Radice D, Solari A; SIMS-Trial group. Giordano A, et al. Among authors: trojano m. J Neurol Sci. 2011 Aug 15;307(1-2):86-91. doi: 10.1016/j.jns.2011.05.008. Epub 2011 May 31. J Neurol Sci. 2011. PMID: 21621796 Clinical Trial.
Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) study.
Bastianello S, Giugni E, Amato MP, Tola MR, Trojano M, Galletti S, Luccichenti G, Quarantelli M, Picconi O, Patti F; COGIMUS study group. Bastianello S, et al. Among authors: trojano m. BMC Neurol. 2011 Oct 14;11:125. doi: 10.1186/1471-2377-11-125. BMC Neurol. 2011. PMID: 21999142 Free PMC article. Clinical Trial.
Experience of an information aid for newly diagnosed multiple sclerosis patients: a qualitative study on the SIMS-Trial.
Borreani C, Giordano A, Falautano M, Lugaresi A, Martinelli V, Granella F, Tortorella C, Plasmati I, Radaelli M, Farina D, Dalla Bella E, Bianchi E, Acquarone N, Miccinesi G, Solari A; SIMS-Trial group. Borreani C, et al. Health Expect. 2014 Feb;17(1):36-48. doi: 10.1111/j.1369-7625.2011.00736.x. Epub 2011 Nov 1. Health Expect. 2014. PMID: 22040528 Free PMC article.
Treating multiple sclerosis with natalizumab.
Iaffaldano P, Lucchese G, Trojano M. Iaffaldano P, et al. Among authors: trojano m. Expert Rev Neurother. 2011 Dec;11(12):1683-92. doi: 10.1586/ern.11.154. Expert Rev Neurother. 2011. PMID: 22091593 Review.
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry.
Hughes S, Spelman T, Trojano M, Lugaresi A, Izquierdo G, Grand'maison F, Duquette P, Girard M, Grammond P, Oreja-Guevara C, Hupperts R, Boz C, Bergamaschi R, Giuliani G, Rio ME, Lechner-Scott J, van Pesch V, Iuliano G, Fiol M, Verheul F, Barnett M, Slee M, Herbert J, Kister I, Vella N, Moore F, Petkovska-Boskova T, Shaygannejad V, Jokubaitis V, McDonnell G, Hawkins S, Kee F, Gray O, Butzkueven H; MSBase Study Group. Hughes S, et al. Among authors: trojano m. J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):305-10. doi: 10.1136/jnnp-2011-301051. Epub 2011 Dec 28. J Neurol Neurosurg Psychiatry. 2012. PMID: 22205675
Increasing age at disability milestones among MS patients in the MSBase Registry.
Kister I, Chamot E, Cutter G, Bacon TE, Jokubaitis VG, Hughes SE, Gray OM, Trojano M, Izquierdo G, Grand'Maison F, Duquette P, Lugaresi A, Grammond P, Boz C, Hupperts R, Petersen T, Giuliani G, Oreja-Guevara C, Iuliano G, Lechner-Scott J, Bergamaschi R, Rio ME, Verheul F, Fiol M, Van Pesch V, Slee M, Butzkueven H, Herbert J; MSBase Investigators. Kister I, et al. Among authors: trojano m. J Neurol Sci. 2012 Jul 15;318(1-2):94-9. doi: 10.1016/j.jns.2012.03.017. Epub 2012 Apr 14. J Neurol Sci. 2012. PMID: 22507751
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study.
Iaffaldano P, Viterbo RG, Paolicelli D, Lucchese G, Portaccio E, Goretti B, Direnzo V, D'Onghia M, Zoccolella S, Amato MP, Trojano M. Iaffaldano P, et al. Among authors: trojano m. PLoS One. 2012;7(4):e35843. doi: 10.1371/journal.pone.0035843. Epub 2012 Apr 25. PLoS One. 2012. PMID: 22558238 Free PMC article.
Immunomodulatory therapies delay disease progression in multiple sclerosis.
Bergamaschi R, Quaglini S, Tavazzi E, Amato MP, Paolicelli D, Zipoli V, Romani A, Tortorella C, Portaccio E, D'Onghia M, Garberi F, Bargiggia V, Trojano M. Bergamaschi R, et al. Among authors: trojano m. Mult Scler. 2016 Nov;22(13):1732-1740. doi: 10.1177/1352458512445941. Epub 2012 May 31. Mult Scler. 2016. PMID: 22653657
467 results